Apellis Pharmaceuticals, Inc

(NASDAQ:APLS)

Latest On Apellis Pharmaceuticals, Inc (APLS):

Date/Time Type Description Signal Details
2023-05-25 17:48 ESTNewsApellis and Sobi to drop ALS candidate on Phase 2 setbackN/A
2023-05-18 17:01 ESTNewsApellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition SpaceN/A
2023-05-06 12:27 ESTNewsApellis Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-06 12:27 ESTNewsApellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 22:14 ESTNewsApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioN/A
2023-05-04 22:14 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.56 misses by $0.10, revenue of $44.84M beats by $18.74MN/A
2023-05-03 20:58 ESTNewsApellis Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-05-01 19:14 ESTNewsApellis weakness on Iveric Bio takeout is buying opportunity - analystN/A
2023-05-01 06:55 ESTNewsApellis Pharmaceuticals (APLS) Presents at the Association for Research in Vision and Ophthalmology Annual Meeting - SlideshowN/A
2023-04-03 17:26 ESTNewsApellis Pharmaceuticals may be worth $90-$100 a share in sale - analystN/A
2023-04-02 23:22 ESTNewsApellis Pharmaceuticals sees takeover interest from large pharma - BloombergN/A
2023-03-24 22:48 ESTNewsApellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy MarketN/A
2023-03-16 14:19 ESTNewsApellis Pharmaceuticals' Empaveli sNDA action date extended by FDAN/A
2023-02-23 11:44 ESTNewsApellis Pharmaceuticals prices $350M in stock offeringN/A
2023-02-22 09:58 ESTNewsApellis Pharmaceuticals to raise $300M in stock and warrants offeringN/A
2023-02-21 21:29 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.50 beats by $0.06, revenue of $22.66M misses by $1.86MN/A
2023-02-18 02:43 ESTNewsApellis wins FDA nod for eye disorder therapyN/A
2023-01-27 18:43 ESTNewsApellis: Empaveli Ought To Win Approval For Eye Disease In February - The Future Looks BrightN/A
2023-01-21 14:26 ESTNewsStocks To Watch: Earnings Heat Up, Healthcare Catalysts And M&A WildcardsN/A
2023-01-05 20:02 ESTNewsApellis appoints Baumal as Chief Medical OfficerN/A
2023-01-04 02:30 ESTNewsApellis, Arvinas lower as Wells Fargo downgrades in 2023 biotech previewN/A
2022-12-15 23:44 ESTNewsApellis Pharmaceuticals: Approval Is Baked Into ValuationN/A
2022-11-18 10:24 ESTNewsApellis surges 17% as FDA accepts to review new data in filing for eye disorder drugN/A
2022-11-11 06:07 ESTNewsApellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA marketN/A
2022-11-08 08:01 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.75 misses by $0.29, revenue of $22.05M beats by $0.46MN/A
2022-11-08 08:00 ESTNewsApellis Pharmaceuticals, Inc. (APLS) Q3 2022 Earnings Call TranscriptN/A
2022-11-05 08:22 ESTNewsApellis Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-11-03 23:08 ESTNewsApellis sinks 20% as FDA review period for eye disease drug extendsN/A
2022-10-16 23:00 ESTNewsCiti lists four more value-creating events in biotech for this yearN/A
2022-09-29 06:33 ESTNewsApellis Pharmaceuticals: Trying To Develop A Blockbuster FranchiseN/A
2022-09-08 07:22 ESTNewsApellis gains as FDA says AdCom unnecessary for eye disease candidateN/A
2022-08-24 16:51 ESTNewsApellis stock dips amid 2-year data of pegcetacoplan for eye disorderN/A
2022-08-09 18:37 ESTNewsApellis Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 18:37 ESTNewsApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 18:56 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.46 misses by $0.09, revenue of $16.32M misses by $0.63MN/A
2022-08-06 06:05 ESTNewsApellis Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-27 15:50 ESTNewsApellis to exchange $75.6M in convertible senior notes for common stockN/A
2022-07-20 18:36 ESTNewsApellis Pharmaceuticals: The Meaning Of Priority Review For Pegcetacoplan For Geographic AtrophyN/A
2022-07-20 03:57 ESTNewsWainwright sees blockbuster potential for Apellis eye degeneration therapy; shares up 22%N/A
2022-07-19 13:21 ESTNewsApellis stock soars 24% as FDA grants priority review to pegcetacoplan for eye disorderN/A
2022-07-19 13:19 ESTNewsH.C. Wainwright sees blockbuster potential for Apellis' treatment in eye degenerationN/A
2022-06-25 15:25 ESTNewsApellis: Mixed Data, But Definitely Approvable In GAN/A
2022-06-13 19:55 ESTNewsHot Stocks: APLS & SKIL both gain, TSLA declined despite upgrade, and VLTA plungedN/A
2022-06-10 11:34 ESTNewsApellis/Sobi Empaveli shows benefit in rare blood disorder patients in new analysesN/A
2022-06-01 11:05 ESTNewsApellis files for FDA approval of pegcetacoplan to treat eye disorderN/A
2022-05-06 19:17 ESTNewsApellis Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-06 19:15 ESTNewsApellis Pharmaceuticals (APLS) Investor Presentation - SlideshowN/A
2022-05-04 22:43 ESTNewsApellis Pharmaceuticals GAAP EPS of -$1.42 misses by $0.12, revenue of $12.1M misses by $0.52MN/A
2022-05-04 22:42 ESTNewsApellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 03:15 ESTNewsApellis Pharmaceuticals Q1 2022 Earnings PreviewN/A

About Apellis Pharmaceuticals, Inc (APLS):

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also develops APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration, as well as is in Phase I/II clinical trial for acute respiratory distress syndrome. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

See Advanced Chart

General

  • Name Apellis Pharmaceuticals, Inc
  • Symbol APLS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 374
  • Fiscal Year EndDecember
  • IPO Date2017-11-09
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.apellis.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 13.99
  • Price/Book (Most Recent Quarter) 18.33
  • Enterprise Value Revenue 12.97
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$6.46
  • Next Year EPS Estimate -$5.31
  • Next Quarter EPS Estimate -$1.60
  • Profit Margin -138%
  • Operating Margin -85%
  • Return on Assets -20%
  • Return on Equity -289%
  • Revenue 250.65 million
  • Earnings Per Share -$3.32
  • Revenue Per Share $3.34
  • Gross Profit -74325000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 3.54 billion
  • Analyst Target Price $64.14
  • Book Value Per Share $2.69
View More

Share Statistics

  • Shares Outstanding 80.38 million
  • Shares Float 59.7 million
  • % Held by Insiders 2117%
  • % Held by Institutions 82.85%
  • Shares Short 8.11 million
  • Shares Short Prior Month 7.75 million
  • Short Ratio 13.44
  • Short % of Float 15%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.52
  • 52 Week High $58.47
  • 52 Week Low $21.84
  • 50 Day Moving Average 46.47
  • 200 Day Moving Average 42.62
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Apellis Pharmaceuticals, Inc (APLS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Apellis Pharmaceuticals, Inc (APLS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A$0.93-$0.45304.58%
2020-09-302020-11-02$646000-$1.79-$1.58-13.31%
2020-06-302020-07-30$N/A-$1.57-$1.34-17.56%
2020-03-312020-04-29$N/A-$2.29-$1.39-64.72%
2019-12-312020-02-27$N/A-$1.77-$1.14-55%
2019-09-302019-11-05$N/A-$1.10-$1.03-6.44%
2019-06-302019-07-31$N/A-$1.12-$0.78-44.39%
2019-03-312019-05-07$N/A-$0.87-$0.68-27.49%
2018-12-312019-02-26$N/A-$0.65-$0.707.58%
2018-09-302018-11-13$N/A-$0.64-$0.697.02%
2018-06-302018-07-31$N/A-$0.61-$0.42-45.86%
2018-03-312018-04-30$N/A-$0.43-$0.27-57.28%
2017-12-312018-03-19$N/A-$0.61-$0.27-129.32%
2017-09-302017-12-20$N/A-$0.23-$0.242.75%

Apellis Pharmaceuticals, Inc (APLS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Apellis Pharmaceuticals, Inc (APLS) Chart:

Apellis Pharmaceuticals, Inc (APLS) News:

Below you will find a list of latest news for Apellis Pharmaceuticals, Inc (APLS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Apellis Pharmaceuticals, Inc (APLS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-12-201053.2CALL0 175.97TRUE00
2024-12-2012.529CALL0 276.18TRUE00
2024-12-201512.5CALL4 5880.24TRUE-1.3-0.09
2024-12-2017.514.67CALL0 378.33TRUE00
2024-12-202019CALL0 675.64TRUE00
2024-12-2022.538.3CALL0 375.61TRUE00
2024-12-20256.6CALL0 7773.88TRUE00
2024-12-20302.89CALL5 1370.86FALSE2.890
2024-12-20351.99CALL0 94575.46FALSE00
2024-12-20400.85CALL3 18572.54FALSE0.850
2024-12-20450.63CALL40 243379.65FALSE-0.27-0.3
2024-12-20500.65CALL0 560FALSE00
2024-12-20550.35CALL43 180388.69FALSE0.10.4
2024-12-20601.6CALL0 8280FALSE00
2024-12-20650.36CALL0 7250FALSE00
2024-12-20700.35CALL0 13110FALSE00
2024-12-20750.26CALL0 1200FALSE00
2024-12-20800.39CALL0 16860FALSE00
2024-12-20854.5CALL0 7990FALSE00
2024-12-20903.5CALL0 2420FALSE00
2024-12-20950.7CALL0 2040FALSE00
2024-12-201000.4CALL0 30FALSE00
2024-12-201054CALL0 240FALSE00
2024-12-201101.55CALL0 10FALSE00
2024-12-201151.2CALL0 10FALSE00
2024-12-201200CALL0 00FALSE00
2024-12-201250CALL0 00FALSE00
2024-12-201301.66CALL0 130FALSE00
2024-12-201350.2CALL0 500FALSE00
2024-12-20100.3PUT0 10FALSE00
2024-12-2012.51PUT0 10FALSE00
2024-12-20153.5PUT0 30FALSE00
2024-12-2017.52.07PUT0 50FALSE00
2024-12-20200.7PUT3 4373.78FALSE0.70
2024-12-2022.50.79PUT0 5674.87FALSE00
2024-12-20252PUT0 4773.73FALSE00
2024-12-20304PUT0 83173.46TRUE00
2024-12-20356.7PUT0 39575.28TRUE00
2024-12-204013.3PUT53 204585.76TRUE13.30
2024-12-20459.54PUT0 8479.7TRUE00
2024-12-205013.3PUT0 53891.94TRUE00
2024-12-205518.6PUT0 13088.84TRUE00
2024-12-206010.4PUT0 2893.17TRUE00
2024-12-206513.4PUT0 0118.63TRUE00
2024-12-20700PUT0 0154.97TRUE00
2024-12-207516PUT0 0120.65TRUE00
2024-12-20800PUT0 0127.16TRUE00
2024-12-208528.9PUT0 0137.46TRUE00
2024-12-209054.2PUT0 0143.25TRUE00
2024-12-209562.6PUT0 0178.37TRUE00
2024-12-201000PUT0 0153.9TRUE00
2024-12-2010545.62PUT0 0196.25TRUE00
2024-12-201100PUT0 0167.28TRUE00
2024-12-201150PUT0 0157.69TRUE00
2024-12-201200PUT0 0203.11TRUE00
2024-12-201250PUT0 0189.41TRUE00
2024-12-201300PUT0 0169.82TRUE00
2024-12-201350PUT0 0184.17TRUE00
2025-01-171052.45CALL0 0126.94TRUE00
2025-01-1712.531.5CALL0 290.81TRUE00
2025-01-17150CALL0 081.03TRUE00
2025-01-1717.531.1CALL0 278.56TRUE00
2025-01-17209.86CALL10 19479.81TRUE-0.74-0.07
2025-01-1722.58.87CALL0 14770.83TRUE00
2025-01-17256CALL13 9275.96TRUE60
2025-01-17304CALL38 22778.89FALSE-0.33-0.08
2025-01-17352.55CALL93 32278.76FALSE-0.05-0.02
2025-01-17401.8CALL866 1096682.38FALSE-0.05-0.03
2025-01-17451.2CALL758 126882.99FALSE0.10.09
2025-01-17500.95CALL6 223287.45FALSE0.950
2025-01-17551.25CALL0 1470FALSE00
2025-01-17600.5CALL22 324489.61FALSE0.170.52
2025-01-17650.3CALL0 7010FALSE00
2025-01-17700.36CALL38 135695.8FALSE0.120.5
2025-01-17750.55CALL0 3710FALSE00
2025-01-17800.3CALL0 2220FALSE00
2025-01-17851.2CALL0 1370FALSE00
2025-01-17900.3CALL0 12714118.03FALSE00
2025-01-17950.5CALL0 2790FALSE00
2025-01-171000.15CALL0 1400FALSE00
2025-01-171055.1CALL0 180FALSE00
2025-01-171102.7CALL0 20FALSE00
2025-01-171150.8CALL0 260FALSE00
2025-01-171200CALL0 00FALSE00
2025-01-171250.25CALL0 2140FALSE00
2025-01-171300.75CALL0 1210FALSE00
2025-01-171350.05CALL0 3650FALSE00
2025-01-17100.3PUT0 90FALSE00
2025-01-1712.50.05PUT0 1090FALSE00
2025-01-17150PUT0 00FALSE00
2025-01-1717.52PUT0 150FALSE00
2025-01-17201.15PUT1 2977.25FALSE0.180.19
2025-01-1722.52PUT1 978.25FALSE0.380.23
2025-01-17252.93PUT37 16475.82FALSE0.550.23
2025-01-17305.8PUT6 33377.33TRUE0.850.17
2025-01-17357.2PUT0 54177.64TRUE00
2025-01-17407.32PUT0 73978.4TRUE00
2025-01-174510.4PUT0 11481.91TRUE00
2025-01-175013.68PUT0 17686.26TRUE00
2025-01-175517.08PUT0 7086.88TRUE00
2025-01-176023.22PUT0 113102.98TRUE00
2025-01-176529.2PUT0 13694.53TRUE00
2025-01-177032.2PUT0 123117.96TRUE00
2025-01-177534.9PUT0 99120.62TRUE00
2025-01-178039.2PUT0 0116.7TRUE00
2025-01-178528.78PUT0 0118.78TRUE00
2025-01-179055.2PUT0 513160.74TRUE00
2025-01-179531.5PUT0 0150.47TRUE00
2025-01-1710041.97PUT0 0128.52TRUE00
2025-01-1710555.9PUT0 0137.82TRUE00
2025-01-1711054.9PUT0 0179.96TRUE00
2025-01-171150PUT0 0152.58TRUE00
2025-01-1712064PUT0 0179.18TRUE00
2025-01-1712576.28PUT0 0192.05TRUE00
2025-01-171300PUT0 0186.64TRUE00
2025-01-1713587.75PUT0 0155.15TRUE00
2025-04-17150CALL0 074.78TRUE00
2025-04-17200CALL0 072.9TRUE00
2025-04-17220CALL0 074.56TRUE00
2025-04-17230CALL0 072.98TRUE00
2025-04-17240CALL0 072.56TRUE00
2025-04-17250CALL0 071.75TRUE00
2025-04-17260CALL0 072.63TRUE00
2025-04-17278.25CALL0 5171.12TRUE00
2025-04-17280CALL0 071.9FALSE00
2025-04-17290CALL0 072.33FALSE00
2025-04-17305.3CALL10 173.07FALSE5.30
2025-04-17310CALL0 072.28FALSE00
2025-04-17324.5CALL1 071.24FALSE4.50
2025-04-17334.2CALL2 071.17FALSE4.20
2025-04-17345CALL0 272.1FALSE00
2025-04-17353.5CALL24 2069.1FALSE-0.5-0.13
2025-04-17363.8CALL0 672.7FALSE00
2025-04-17373.9CALL0 272.71FALSE00
2025-04-17380CALL0 071.57FALSE00
2025-04-17393CALL1 073.78FALSE30
2025-04-17402.75CALL2 1572.93FALSE-0.21-0.07
2025-04-17413.4CALL0 171.89FALSE00
2025-04-17422.3CALL0 471.33FALSE00
2025-04-17432.1CALL709 70770.59FALSE2.10
2025-04-17440CALL0 071.85FALSE00
2025-04-17453.07CALL0 1672.65FALSE00
2025-04-17502.5CALL0 50FALSE00
2025-04-17551.62CALL0 30FALSE00
2025-04-17601.01CALL0 90FALSE00
2025-04-17150PUT0 00FALSE00
2025-04-17201.88PUT254 572.31FALSE1.880
2025-04-17220PUT0 073.37FALSE00
2025-04-17230PUT0 072.53FALSE00
2025-04-17243.3PUT1 069.13FALSE3.30
2025-04-17253.97PUT13 971.76FALSE0.50.14
2025-04-17260PUT0 071.91FALSE00
2025-04-17274PUT0 172.59FALSE00
2025-04-17284.5PUT0 17072.25TRUE00
2025-04-17295.1PUT0 19572.23TRUE00
2025-04-17307PUT1 773.76TRUE70
2025-04-17316.1PUT0 171.89TRUE00
2025-04-17320PUT0 071.62TRUE00
2025-04-17330PUT0 072.31TRUE00
2025-04-17348.3PUT0 471.52TRUE00
2025-04-17358.6PUT0 3071.11TRUE00
2025-04-17369.2PUT0 172.37TRUE00
2025-04-17379.9PUT0 171.51TRUE00
2025-04-173810.1PUT0 171.73TRUE00
2025-04-17390PUT0 071.75TRUE00
2025-04-17400PUT0 072.27TRUE00
2025-04-17410PUT0 071.95TRUE00
2025-04-17420PUT0 072.86TRUE00
2025-04-174310.2PUT0 1771.43TRUE00
2025-04-17440PUT0 071.25TRUE00
2025-04-174515.69PUT0 373.28TRUE00
2025-04-175014.47PUT0 974.94TRUE00
2025-04-175518.15PUT0 775.62TRUE00
2025-04-17600PUT0 077.29TRUE00
2026-01-16150CALL0 063.31TRUE00
2026-01-162021.46CALL0 264.27TRUE00
2026-01-1622.537.3CALL0 164.31TRUE00
2026-01-162510.78CALL0 3864.4TRUE00
2026-01-16308.1CALL783 25468.17FALSE-0.39-0.05
2026-01-16355.71CALL1416 5860.46FALSE-1.69-0.23
2026-01-16404.6CALL708 2960.7FALSE4.60
2026-01-16454.6CALL8 25762.26FALSE4.60
2026-01-16503.05CALL5 3961.03FALSE-1.15-0.27
2026-01-16553.39CALL0 37961.54FALSE00
2026-01-16603.28CALL0 10080FALSE00
2026-01-16652.09CALL0 3990FALSE00
2026-01-16701.1CALL10 35957.03FALSE1.10
2026-01-16751.25CALL10 4261.9FALSE1.250
2026-01-16802.6CALL0 11560.74FALSE00
2026-01-16850.65CALL2 34957.76FALSE0.650
2026-01-16901.75CALL0 840FALSE00
2026-01-16952.2CALL0 240FALSE00
2026-01-161007.29CALL0 270FALSE00
2026-01-161056.5CALL0 1040FALSE00
2026-01-16150PUT0 00FALSE00
2026-01-16203.5PUT0 11965.59FALSE00
2026-01-1622.52.54PUT0 4865.44FALSE00
2026-01-16255.7PUT0 14764.87FALSE00
2026-01-16308.23PUT0 16364.06TRUE00
2026-01-163510.92PUT0 8763.12TRUE00
2026-01-164014.2PUT0 236361.42TRUE00
2026-01-164513.2PUT0 57362.76TRUE00
2026-01-165023PUT0 35463.25TRUE00
2026-01-165528.37PUT4 72863.19TRUE28.370
2026-01-166021PUT0 2652.99TRUE00
2026-01-166537PUT0 2763.53TRUE00
2026-01-167032.95PUT0 8774.71TRUE00
2026-01-167539.8PUT0 3173.9TRUE00
2026-01-168042.5PUT0 2976.69TRUE00
2026-01-168548.91PUT0 7982.37TRUE00
2026-01-169057.55PUT0 079.81TRUE00
2026-01-16950PUT0 079.16TRUE00
2026-01-1610068.25PUT0 087.4TRUE00
2026-01-161050PUT0 083.03TRUE00
2027-01-15150CALL0 064.39TRUE00
2027-01-15200CALL0 064.28TRUE00
2027-01-15230CALL0 065.31TRUE00
2027-01-152514.1CALL0 362.9TRUE00
2027-01-152810.86CALL1 163.41FALSE10.860
2027-01-15300CALL0 161.72FALSE00
2027-01-15330CALL0 062.61FALSE00
2027-01-153510CALL2 061.38FALSE100
2027-01-15370CALL0 060.9FALSE00
2027-01-15400CALL0 060.87FALSE00
2027-01-15420CALL0 060.53FALSE00
2027-01-15450CALL0 060.16FALSE00
2027-01-15470CALL0 060.04FALSE00
2027-01-15500CALL0 059.75FALSE00
2027-01-15556.59CALL0 158.28FALSE00
2027-01-15150PUT0 00FALSE00
2027-01-15204.38PUT0 163.54FALSE00
2027-01-15235.9PUT0 165.24FALSE00
2027-01-15257.01PUT2 060.46FALSE7.010
2027-01-15280PUT0 063.43TRUE00
2027-01-15309.7PUT0 1262.48TRUE00
2027-01-15330PUT0 061.97TRUE00
2027-01-15350PUT0 062.23TRUE00
2027-01-15370PUT0 061.61TRUE00
2027-01-15400PUT0 060.68TRUE00
2027-01-15420PUT0 060.08TRUE00
2027-01-15450PUT0 060.24TRUE00
2027-01-15470PUT0 060.15TRUE00
2027-01-155023.93PUT0 259.21TRUE00
2027-01-155526.6PUT0 659.74TRUE00

Latest APLS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST5$39.4
Jun 13, 2022 7:59 PM EST25$39.4
Jun 13, 2022 7:59 PM EST86$39.39
Jun 13, 2022 7:59 PM EST14$39.4
Jun 13, 2022 7:59 PM EST32$39.4

Apellis Pharmaceuticals, Inc (APLS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000083423720004741/0000834237-20-004741-index.htm
2020-02-053/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320003295/0000899243-20-003295-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004262/0000899243-20-004262-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004264/0000899243-20-004264-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004268/0000899243-20-004268-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004275/0000899243-20-004275-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004281/0000899243-20-004281-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004288/0000899243-20-004288-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004299/0000899243-20-004299-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004303/0000899243-20-004303-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004312/0000899243-20-004312-index.htm
2020-02-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320004314/0000899243-20-004314-index.htm
2020-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320008068/0000899243-20-008068-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320027595/0000899243-20-027595-index.htm
2020-10-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000089924320027598/0000899243-20-027598-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000090221920000352/0000902219-20-000352-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000090266420001196/0000902664-20-001196-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1492422/000092963820000336/0000929638-20-000336-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220013334/0001127602-20-013334-index.htm
2020-04-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220013338/0001127602-20-013338-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014100/0001127602-20-014100-index.htm
2020-04-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220014554/0001127602-20-014554-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220016304/0001127602-20-016304-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-05-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220017181/0001127602-20-017181-index.htm
2020-06-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019258/0001127602-20-019258-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019731/0001127602-20-019731-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220019735/0001127602-20-019735-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-07-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220021646/0001127602-20-021646-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220022885/0001127602-20-022885-index.htm
2020-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220023992/0001127602-20-023992-index.htm
2020-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220024043/0001127602-20-024043-index.htm
2020-09-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220024640/0001127602-20-024640-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220025183/0001127602-20-025183-index.htm
2020-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026264/0001127602-20-026264-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027098/0001127602-20-027098-index.htm
2020-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-11-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1492422/000112760220027991/0001127602-20-027991-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520052855/0001193125-20-052855-index.htm
2020-02-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520052867/0001193125-20-052867-index.htm
2020-04-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520098977/0001193125-20-098977-index.htm
2020-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1492422/000119312520115068/0001193125-20-115068-index.htm
2020-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1492422/000119312520115084/0001193125-20-115084-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520135621/0001193125-20-135621-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520141579/0001193125-20-141579-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520157384/0001193125-20-157384-index.htm
2020-10-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1492422/000119312520277496/0001193125-20-277496-index.htm
2010-05-19DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1492242/000149224210000001/0001492242-10-000001-index.htm
2020-02-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1492422/000156459020007350/0001564590-20-007350-index.htm
2020-04-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020019689/0001564590-20-019689-index.htm
2020-07-3010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020034763/0001564590-20-034763-index.htm
2020-11-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1492422/000156459020049423/0001564590-20-049423-index.htm
2020-08-24CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1492422/999999999720004458/9999999997-20-004458-index.htm

Apellis Pharmaceuticals, Inc (APLS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Apellis Pharmaceuticals, Inc (APLS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2117%
Institutional Ownership: 8285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-02-13Pascal DeschateletsChief Operating OfficerSell55,398.0040.982,270,154.641,008,681.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerSell5,000.0040.67203,330.001,027,430.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerSell30,637.0040.661,245,792.331,032,430.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell300.0023.867,158.001,053,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell3,212.0022.2871,556.941,053,367.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell15,065.0021.58325,087.641,056,579.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-02-19Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,058,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-18Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,063,067.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006654/0001127602-20-006654-index.htm
2020-02-13Pascal DeschateletsChief Operating OfficerBuy117,205.002.14250,818.701,064,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-10Cedric FrancoisChief Executive OfficerBuy34,375.001,066,805.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004299/0000899243-20-004299-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell12,060.0020.69249,557.581,071,644.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-10-15Cedric FrancoisChief Executive OfficerSell5,000.0034.46172,300.001,083,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027098/0001127602-20-027098-index.htm
2020-03-17Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,083,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell700.0022.2915,600.201,083,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell2,192.0021.5747,279.251,084,404.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerSell2,108.0020.7343,694.621,086,596.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-09-15Cedric FrancoisChief Executive OfficerSell5,000.0030.96154,800.001,088,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220025183/0001127602-20-025183-index.htm
2020-03-16Cedric FrancoisChief Executive OfficerBuy30,637.002.1465,563.181,088,704.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011263/0001127602-20-011263-index.htm
2020-08-20Cedric FrancoisChief Executive OfficerSell3,457.0030.00103,710.001,093,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220024043/0001127602-20-024043-index.htm
2020-08-18Cedric FrancoisChief Executive OfficerSell1,543.0030.0046,290.001,096,536.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220023992/0001127602-20-023992-index.htm
2020-07-15Cedric FrancoisChief Executive OfficerSell5,000.0032.12160,600.001,098,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220021646/0001127602-20-021646-index.htm
2020-06-15Cedric FrancoisChief Executive OfficerSell5,000.0030.21151,050.001,103,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019731/0001127602-20-019731-index.htm
2020-05-15Cedric FrancoisChief Executive OfficerSell5,000.0029.92149,600.001,108,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017181/0001127602-20-017181-index.htm
2020-04-15Cedric FrancoisChief Executive OfficerSell5,000.0029.77148,850.001,113,079.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014100/0001127602-20-014100-index.htm
2020-02-10LUKAS SCHEIBLEROfficerBuy9,375.0012,310.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004314/0000899243-20-004314-index.htm
2020-10-07Victoria L. BrownProgram Team LeadBuy12,000.0018.98227,760.0015,607.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-02-10Timothy Eugene SullivanChief Financial OfficerBuy11,688.0023,387.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004303/0000899243-20-004303-index.htm
2020-02-10Nicole D PerryVice President - FinanceBuy2,500.002,500.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004275/0000899243-20-004275-index.htm
2020-02-10Ahmad SadrOfficerBuy2,725.002,725.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004264/0000899243-20-004264-index.htm
2020-11-02Federico GrossiCHIEF MEDICAL OFFICERSell600.0031.0918,654.0027,725.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027991/0001127602-20-027991-index.htm
2020-10-01Federico GrossiOfficerSell600.0030.2218,132.0028,325.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026264/0001127602-20-026264-index.htm
2020-09-01Federico GrossiOfficerSell600.0031.5818,948.0028,925.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220024640/0001127602-20-024640-index.htm
2020-08-03Federico GrossiOfficerSell600.0026.2815,768.0029,525.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220022885/0001127602-20-022885-index.htm
2020-07-01Federico GrossiOfficerSell850.0032.4327,565.5030,125.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220021048/0001127602-20-021048-index.htm
2020-06-15Federico GrossiOfficerSell856.0030.2125,859.7630,975.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019735/0001127602-20-019735-index.htm
2020-02-10Federico GrossiOfficerBuy9,375.0031,831.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004262/0000899243-20-004262-index.htm
2020-02-10David O. WatsonGeneral CounselSell5,000.0044.50222,500.0035,417.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-10-07Victoria L. BrownProgram Team LeadSell12,000.0035.00420,000.003,607.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026748/0001127602-20-026748-index.htm
2020-02-10David O. WatsonGeneral CounselBuy6,375.0040,417.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-02-10David O. WatsonGeneral CounselBuy7,505.002.6720,038.3542,922.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004260/0000899243-20-004260-index.htm
2020-05-08PAUL R. FONTEYNEDirectorBuy5,000.0031.81159,034.005,000.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220016304/0001127602-20-016304-index.htm
2020-02-10Lucia CelonaOfficerBuy5,213.005,213.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004281/0000899243-20-004281-index.htm
2020-02-14Alec MachielsDirectorSell2,500.0042.35105,875.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-03-25Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-15Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-05-15Alec MachielsDirectorSell2,500.0030.0075,000.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-06-15Alec MachielsDirectorSell2,500.0030.2175,525.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-10-07Alec MachielsDirectorSell7,500.0035.00262,500.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-10-15Alec MachielsDirectorSell2,500.0035.0087,500.00669,544.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-02-14Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220006429/0001127602-20-006429-index.htm
2020-03-25Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220011988/0001127602-20-011988-index.htm
2020-04-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220014098/0001127602-20-014098-index.htm
2020-05-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220017178/0001127602-20-017178-index.htm
2020-06-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220019733/0001127602-20-019733-index.htm
2020-10-15Alec MachielsDirectorBuy2,500.002.676,675.00672,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220027101/0001127602-20-027101-index.htm
2020-10-07Alec MachielsDirectorBuy7,500.002.6720,025.00677,044.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220026750/0001127602-20-026750-index.htm
2020-02-10Thomas A. LacknerOfficerBuy2,725.007,725.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004268/0000899243-20-004268-index.htm
2020-02-10Pascal DeschateletsChief Operating OfficerBuy9,375.00891,118.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004312/0000899243-20-004312-index.htm
2020-02-10Adam J. TownsendOfficerBuy9,375.009,375.00https://www.sec.gov/Archives/edgar/data/1492422/000089924320004288/0000899243-20-004288-index.htm
2020-02-12Pascal DeschateletsChief Operating OfficerSell52,075.0042.802,228,966.23946,874.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm
2020-02-12Pascal DeschateletsChief Operating OfficerBuy117,206.002.14250,820.84998,949.00https://www.sec.gov/Archives/edgar/data/1492422/000112760220005685/0001127602-20-005685-index.htm